Table 2.
Summary of tumour characteristics
| Author | Year | Tumour characteristics |
||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Proportion of recurrent disease (%) |
CIS (%) |
Low-risk disease (%) |
Multifocal disease (%) |
|||||||
| PDD | WL | PDD | WL | PDD | WL | PDD | WL | |||
| HAL | Hermann [23] | 2011 | No data | No data | 84 | 90 | 35 | 38 | ||
| Geavlete [24] | 2012 | No data | 14.7 | 12.3 | 59.6 (Ta) | 60.7 (Ta) | 64.7 | 68 | ||
| Karaolides [25] | 2012 | 29.3 | 31.4 | 11.1 | 7.3 | 17.1 | 26.7 | 56.1 | 42.2 | |
| O'Brien [17] | 2013 | 0 | 0 | 0 | 1.1 | 50.5 | 56.8 | 54 | 66 | |
| Gkritsios [26] | 2014 | 73 | 48 | No data | 16.7 | 16.2 | No data | |||
| Drăgoescu [27] | 2017 | 0 | 0 | 5.2 | 10.5 | 28.6 (Ta) | 29.8 (Ta) | No data | ||
| 5-ALA | Filbeck [14] | 2002 | 30.7 | 18.4 | 5.7 | 4.9 | 35.2 | 48.5 | 37.5 | 23.3 |
| Babjuk [28] | 2005 | 66.6 | 54.8 | No data | 63.4 (Ta) | 59.7 (Ta) | 75 | 63.2 | ||
| Daniltchenko [29] | 2005 | No data | 0 | 1.9 | 78.4 | 78.4 | 62.8 | 39.2 | ||
| Schumacher [30] | 2010 | 52.5 | 50 | 0.7 | 4.3 | 54.6 | 47.8 | 46.8 | 44.2 | |
| Stenzl [31] | 2011 | No data | 1.6 | 1.7 | 33.3 | 28.4 | 43.2 | 36.4 | ||
| Rolevich [32] | 2017 | 34.4 | 29.5 | 1.8 | 2.5 | 15.6 | 16.3 | 55.4 | 59.1 | |
5-ALA = 5-aminolaevulinic acid; CIS = carcinoma in situ; HAL = hexaminolaevulinate; PDD = photodynamic diagnosis; WL = white light.